Epidemiology of low dose aspirin damage in the lower gastrointestinal tract

Current Pharmaceutical Design

Volumn 21, Issue 35, 2015, Pages 5094-5100

  Sostres, Carlos ^a,b,c,d   Lanas, Angel ^a,b,c,d  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^d UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

Epidemiology; Low dose aspirin; Lower gastrointestinal damage; Mortality; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; REBAMIPIDE; RIFAXIMIN; ANTITHROMBOCYTIC AGENT;

ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; COLONOSCOPY; ENTEROPATHY; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPOALBUMINEMIA; INTESTINE DIVERTICULOSIS; INTESTINE ENDOSCOPY; INTESTINE INJURY; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; INTESTINE ULCER; IRON DEFICIENCY ANEMIA; LOW DRUG DOSE; NONHUMAN; OCCULT BLOOD; PATHOGENESIS; PETECHIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY PREVENTION; SYSTEMATIC REVIEW (TOPIC); ANIMAL; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL ENDOSCOPY; LOWER GASTROINTESTINAL TRACT; PATHOLOGY; PROCEDURES;

ANIMALS; ASPIRIN; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOSCOPY, GASTROINTESTINAL; GASTROINTESTINAL DISEASES; HUMANS; LOWER GASTROINTESTINAL TRACT; PLATELET AGGREGATION INHIBITORS;

EID: 84947983658     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150915110204     Document Type: Article

References (86)

1. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.
2. Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101: 1206-18.
3. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
4. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
5. Kim C, Beckles GL. Cardiovascular disease risk reduction in the Behavioral Risk Factor Surveillance System. Am J Prev Med 2004; 27: 1-7.
6. Esmatjes E, Castell C, Franch J, Puigoriol E, Hernandez R. Acetylsalicylic acid consumption in patients with diabetes mellitus [Spanish]. Med Clin (Barc) 2003; 122: 96-8.
7. Loll PJ, Picot D, Garavoto RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 1995; 2: 637-43.
8. Lanas A. Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice. Expert Opin Drug Saf 2011; 10(1): 45-54.
9. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310: 827-30.
10. Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005; 22: 795-801.
11. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008; 52: 1502-17.
12. Higuchi K, Umegaki E, Watanabe T, et al. Present status and strategy of NSAIDs-induced small bowel injury. J Gastroenterol 2009; 44: 879-88.
13. Sostres C, Lanas A. Gastrointestinal effects of aspirin. Nature Rev Gastroenterol Hepatol 2011; 8: 385-94.
14. Sigthorsson G, Simpson RJ, Walley M, et al. COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology 2002; 122: 1913-23.
15. Reuter BK, Davies NM, Wallace JL. Nonsteroidal antiinflammatory drug enteropathy in rats: role of permeability, bacteria and enterohepatic circulation. Gastroenterology 1997; 112: 109- 17.
16. Robert A, Asano T. Resistance of germfree rats to indomethacininduced intestinal lesions. Prostaglandins 1977; 14: 333-41.
17. Wax J, Clinger WA, Varner P, Bass P, Winder CV. Relationship of the enterohepatic cycle to ulcerogenesis in the rat small bowel with the flufenamic acid. Gastroenterology 1970; 58: 772-80.
18. Miura S, Suematsu M, Tanaka S. Microcirculatory disturbamce in indomethacin-induced intestinal ulcer. Am J Physiol 1991; 261: G214-9.
19. Bjarnason I, Williams P, Smethurst P, Peters TJ, Levi AJ. Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine. Gut1986; 27: 1292-7.
20. Sigthorsson G, Tibble J, Hayllar J, et al. Intestinal permeability and inflammation in patients on NSAIDs. Gut 1998; 43: 506-11.
21. Catanoso M, Lo Gullo R, Giofré MR, et al. Gastro-intestinal permeability is increased in patients with limited systemic sclerosis. Scand J Rheumatol 2001; 30: 77-81.
22. Jenkins RT, Rooney PJ, Jones DB, Bienenstock J, Goodacre RL. Increased intestinal permeability in patients with rheumatoid arthritis: a side-effect of oral nonsteroidal anti-inflammatory drug therapy? Br J Rheumatol 1987; 26: 103-7.
23. Leung WK, Bjarnason I, Wong VW, Sung JJ, Chan FK. Small bowel enteropathy associated with chronic low-dose aspirin therapy. Lancet 2007; 369: 614.
24. Somasundaram S, Rafi S, Hayllar J, et al. Mitochondrial damage: a possible mechanism of the ''topical'' phase of NSAID induced injury to the rat intestine. Gut 1997; 41: 344-53.
25. Twiss IM, Burggraaf J, Schoemaker RC, et al. The sugar absorption test in the evaluation of the gastrointestinal intolerance to bisphosphonates: studies with oral pamidronate. Clin Pharmacol Ther 2001; 69: 431-7.
26. Moore RA, Derry S, McQuay HJ. Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromium-labelled erythrocytes. Arthritis Res Ther 2008; 10: R7.
27. Fortun PJ, Hawkey CJ. Nonsteroidal antiinflammatory drugs and the small intestine. Curr Opin Gastroenterol 2005; 21: 169-75.
28. Endo H, Hosono K, Inamori M, et al. Incidence of small bowel injury induced by low-dose aspirin: a crossover study using capsule endoscopy in healthy volunteers. Digestion 2009; 79: 44-51.
29. Smecuol E, Pinto Sanchez MI, Suarez A, et al. Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. Clin Gastroenterol Hepatol 2009; 7(5): 524-9.
30. Shiotani A, Haruma K, Nishi R, et al. Randomized, double-blind, pilot study of geranylgeranylacetone versus placebo in patients taking low-dose entericcoated aspirin. Low-dose aspirin-induced small bowel damage. Scand J Gastroenterol 2010; 45: 292-8.
31. Mizukami K, Murakami K, Abe T, et al. Aspirin-induced small bowel injuries and the preventive effect of rebamipide. World J Gastroenterol 2011; 17: 5117-22.
32. Endo H, Hosono K, Inamori M, et al. Characteristics of small bowel injury in symptomatic chronic low-dose aspirin users: the experience of two medical centers in capsule endoscopy. J Gastroenterol 2009; 44: 544-9.
33. Watanabe T, Sugimori S, Kameda N, et al. Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol 2008; 6: 1279-82.
34. Shiotani A, Honda K, Murao T, et al. Combination of low-dose aspirin and thienopyridine exacerbates small bowel injury. Scand J Gastroenterol 2011; 46: 281-6.
35. Watari I, Oka S, Tanaka S, et al. Effectiveness of polaprezinc for low-dose aspirin-induced small-bowel mucosal injuries as evaluated by capsule endoscopy: a pilot randomized controlled study. BMC Gastroenterol 2013; 13: 108.
36. Watari I, Oka S, Tanaka S, et al. Comparison of small-bowel mucosal injury between low-dose aspirin and non-aspirin non-steroidal anti-inflammatory drugs: a capsule endoscopy study. Digestion 2014; 89: 225-31.
37. Endo H, Hosono K, Higurashi T, et al. Quantitative analysis of lowdose aspirin-associated small bowel injury using a capsule endoscopy scoring index. Dig Endosc 2011; 23: 56-61.
38. Endo H, Higurashi T, Hosono K, et al. Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. J Gastroenterol 2011; 46: 894-905.
39. Matsumoto T, Kudo T, Esaki M, et al. Prevalence of non-steroidal anti-inflammatory drug-induced enteropathy determined by doubleballoon endoscopy: a Japanese multicenter study. Scand J Gastroenterol 2008; 43: 490-6.
40. Watari I, Oka S, Tanaka S, et al. Comparison of small-bowel mucosal injury between low-dose aspirin and non-aspirin non-steroidal anti-inflammatory drugs: a capsule endoscopy study. Digestion 2014; 89(3): 225-31.
41. Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993; 104: 1832-47.
42. Laine L, Smith R, Min K, Chen C, Dubois RW. Systematic review: the lower gastrointestinal adverse effects of non-steroidal antiinflammatory drugs. Aliment Pharmacol Ther 2006; 24: 751-67.
43. Longstreth GF. Epidemiology and outcome of patients hospitalized with acute lower gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol 1997; 92: 419-24.
44. Tsuruoka N, Iwakiri R, Hara M, et al. NSAIDs are a significant risk factor for colonic diverticular hemorrhage in elder patients: evaluation by a case-control study. J Gastroenterol Hepatol 2011; 26: 1047-52.
45. Niikura R, Nagata N, Yamada A, Akiyama J, Shimbo T, Uemura N. Recurrence of colonic diverticular bleeding and associated risk factors. Colorectal Dis 2012; 14: 302-5.
46. Jansen A, Harenberg S, Grenda U, Elsing C. Risk factors for colonic diverticular bleeding: a westernized community based hospital study. World J Gastroenterol 2009; 15: 457-61.
47. Foutch PG. Diverticular bleeding: are nonsteroidal antiinflammatory drugs risk factors for hemorrhage and can colonoscopy predict outcome for patients? Am J Gastroenterol 1995; 90: 1779-84.
48. Aldoori WH, Giovannucci EL, Rimm EB, Wing AL, Willett WC. Use of acetaminophen and nonsteroidal anti-inflammatory drugs: a prospective study and the risk of symptomatic diverticular disease in men. Arch Fam Med 1998; 7: 255-60.
49. Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT. Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding. Gastroenterology 2011; 140: 1427-33.
50. Strate LL, Liu YL, Aldoori WH, Syngal S, Giovannucci EL. Obesity increases the risks of diverticulitis and diverticular bleeding. Gastroenterology 2009; 136: 115-22.
51. Okamoto T, Watabe H, Yamada A, Hirata Y, Yoshida H, Koike K. The association between arteriosclerosis related diseases and diverticular bleeding. Int J Colorectal Dis 2012; 27: 1161-6.
52. Campbell K, Steele RJ. Non-steroidal anti-inflammatory drugs and complicated diverticular disease: a case-control study. Br J Surg 1991; 78: 190-1.
53. Wilson RG, Smith AN, Macintyre IM. Complications of diverticular disease and non-steroidal anti-inflammatory drugs: a prospective study. Br J Surg 1990; 77: 1103-4.
54. Nagata N, Niikura R, Aoki T, et al. Colonic diverticular hemorrhage associated with the use of nonsteroidal anti-inflammatory drugs, low-doseaspirin, antiplatelet drugs, and dual therapy. Gastroenterol Hepatol 2014; 29(10): 1786-93.
55. Yuhara H, Corley DA, Nakahara F, et al. Aspirin and nonaspirin NSAIDs increase risk of colonic diverticular bleeding: a systematic review and meta-analysis. J Gastroenterol 2014; 49(6): 992-1000.
56. Lanas A, Garcia-Rodriguez LA, Polo-Tomas M, et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol 2009; 104: 1633-41.
57. Arroja B, Cremers I, Ramos R, et al. Acute lower gastrointestinal bleeding management in Portugal: a multicentric prospective 1-year survey. Eur J Gastroenterol Hepatol 2011; 23: 317-22.
58. Makela JT, Kiviniemi H, Laitinen S, Kairaluoma MI. Diagnosis and treatment of acute lower gastrointestinal bleeding. Scand J Gastroenterol 1993; 28: 1062-6.
59. Lanas A, Sekar MC, Hirschowitz BI. Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding. Gastroenterology 1992; 103(3): 862-9.
60. Hreinsson JP, Gumundsson S, Kalaitzakis E, Björnsson ES. Lower gastrointestinal bleeding: incidence, etiology, and outcomes in a population-based setting. Eur J Gastroenterol Hepatol 2013; 25(1): 37-43.
61. Gayer C, Chino A, Lucas C, et al. Acute lower gastrointestinal bleeding in 1112 patients admitted to an urban emergency medical center. Surgery 2009; 146: 600-6.
62. Lanas A, Serrano P, Bajador E, et al. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology1997; 112: 683-9.
63. Langman MJ, Morgan L, Worrall A. Use of antiinflammatorydrugs by patients admitted with small or large bowel perforations and haemorrhage. Br Med J 1985; 290: 347-9.
64. Wilcox CM, Alexander LN, Cotsonis GA, et al. Nonsteroidal antiinflammatory drugs are associated with both upper and lower gastrointestinal bleeding. Dig Dis Sci 1997; 42: 990-7.
65. Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003; 124: 288-92.
66. Lanas A, Carrera-Lasfuentes P, Arguedas Y, et al. Risk of Upper and Lower Gastrointestinal Bleeding in Patients Taking Nonsteroidal Anti-inflammatory Drugs, Antiplatelet Agents, or Anticoagulants. Clin Gastroenterol Hepatol 2015; 13(5): 906-12.
67. Lanas A, Perez-Aisa MA, Feu F, et al. Investigators of the Asociación Española de Gastroenterología (AEG). A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005; 100(8): 1685-93.
68. Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin 2007; 23: 163-73.
69. Endo H, Sakai E, Taniguchi L, et al. Risk factors for small-bowel mucosal breaks in chronic low-dose aspirin users: data from a prospective multicenter capsule endoscopy registry. Gastrointest Endosc 2014; 80(5): 826-34.
70. Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011; 141(4): 1314-22.
71. Lanas Á, Carrera-Lasfuentes P, Arguedas Y, et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol 2015; 13(5): 906-12.
72. Burger W, Chemnitius JM, Kneissl GD, et al. Low-dose aspirin for secondary cardiovascular prevention-cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation- review and meta-analysis. J Intern Med 2005; 257: 399-414.
73. Biondi-Zoccai G,Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50 279 patients at risk for coronary artery disease. Eur Heart J 2006; 27: 2667-74.
74. Sibon I, Orgogozo JM. Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology 2004; 62 (7): 1187-9.
75. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999; 354: 635-9.
76. Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7: 1202-9.
77. Watanabe T, Nishio H, Tanigawa T, et al. Probiotic Lactobacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid. Am J Physiol Gastrointest Liver Physiol 2009; 297: G506-13.
78. Montalto M, Gallo A, Curigliano V, et al. Clinical trial: the effects of a probiotic mixture on non-steroidal anti-inflammatory drug enteropathy- a randomized, double-blind, cross-over, placebocontrolled study. Aliment Pharmacol Ther 2010; 32: 209-14.
79. Park SH, Cho CS, Lee OY, et al. Comparison of prevention of NSAID-induced gastrointestinal complications by rebamipide and misoprostol: a randomized, multicenter, controlled trial-STORM STUDY. J Clin Biochem Nutr 2007; 40: 148-55.
80. Terano A, Arakawa T, Sugiyama T, et al. Rebamipide, a gastroprotective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial. J Gastroenterol 2007; 42: 690-3.
81. Kim HK, Kim JI, Kim JK, et al. Preventive effects of rebamipide on NSAID-induced gastric mucosal injury and reduction of gastric mucosal blood flow in healthy volunteers. Dig Dis Sci 2007; 52: 1776-82.
82. Fujimori S, Takahashi Y, Gudis K, et al. Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a double-blind, randomized, controlled trial evaluated by capsule endoscopy. J Gastroenterol 2011; 46: 57-64.
83. Niwa Y, Nakamura M, Ohmiya N, et al. Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a retrospective, randomized, double-blinded, placebocontrolled, cross-over study. J Gastroenterol 2008; 43: 270-6.
84. Kurokawa S, Katsuki S, Fujita T, et al. A randomized, doubleblinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and/or non-steroidal anti-inflammatory drug induced small bowel injury. J Gastroenterol 2014; 49: 239-44.
85. Ciobanu L, Taulescu M, Prundus R, et al. Effects of rifaximin on indomethacin-induced intestinal damage in guinea-pigs. Eur Rev Med Pharmacol Sci 2014; 18(3): 344-51.
86. Shiotani A, Murao T, Fujita Y, et al. Single nucleotide polymorphism markers for low-dose aspirin-associated peptic ulcer and ulcer bleeding. J Gastroenterol Hepatol 2014; 29 Suppl 4: 47-52.